Entera Bio Stock Performance
| ENTX Stock | USD 1.37 0.09 6.16% |
The firm shows a Beta (market volatility) of -1.08, which means a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Entera Bio are expected to decrease slowly. On the other hand, during market turmoil, Entera Bio is expected to outperform it slightly. At this point, Entera Bio has a negative expected return of -1.06%. Please make sure to confirm Entera Bio's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Entera Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 11.1 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Entera Bio Relative Risk vs. Return Landscape
If you would invest 284.00 in Entera Bio on November 3, 2025 and sell it today you would lose (147.00) from holding Entera Bio or give up 51.76% of portfolio value over 90 days. Entera Bio is currently does not generate positive expected returns and assumes 4.6604% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Entera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entera Bio Target Price Odds to finish over Current Price
The tendency of Entera Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.37 | 90 days | 1.37 | about 91.81 |
Based on a normal probability distribution, the odds of Entera Bio to move above the current price in 90 days from now is about 91.81 (This Entera Bio probability density function shows the probability of Entera Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Entera Bio has a beta of -1.08 suggesting Additionally Entera Bio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Entera Bio Price Density |
| Price |
Predictive Modules for Entera Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entera Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entera Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entera Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Entera Bio is not an exception. The market had few large corrections towards the Entera Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entera Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entera Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.03 | |
β | Beta against Dow Jones | -1.08 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | -0.24 |
Entera Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entera Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entera Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Entera Bio generated a negative expected return over the last 90 days | |
| Entera Bio may become a speculative penny stock | |
| Entera Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 181 K. Net Loss for the year was (9.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entera Bio currently holds about 17.28 M in cash with (6.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 25.0% of the company shares are held by company insiders |
Entera Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Entera Stock often depends not only on the future outlook of the current and potential Entera Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Entera Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.7 M | |
| Cash And Short Term Investments | 8.7 M |
Entera Bio Fundamentals Growth
Entera Stock prices reflect investors' perceptions of the future prospects and financial health of Entera Bio, and Entera Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entera Stock performance.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (87.29) % | ||||
| Current Valuation | 58.59 M | ||||
| Shares Outstanding | 45.86 M | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 4.39 X | ||||
| Price To Sales | 506.65 X | ||||
| Revenue | 181 K | ||||
| EBITDA | (9.54 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 272 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (6.82 M) | ||||
| Earnings Per Share | (0.23) X | ||||
| Total Asset | 9.39 M | ||||
| Retained Earnings | (113.93 M) | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
About Entera Bio Performance
Evaluating Entera Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Entera Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entera Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.Things to note about Entera Bio performance evaluation
Checking the ongoing alerts about Entera Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entera Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entera Bio generated a negative expected return over the last 90 days | |
| Entera Bio may become a speculative penny stock | |
| Entera Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 181 K. Net Loss for the year was (9.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entera Bio currently holds about 17.28 M in cash with (6.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 25.0% of the company shares are held by company insiders |
- Analyzing Entera Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entera Bio's stock is overvalued or undervalued compared to its peers.
- Examining Entera Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entera Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entera Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entera Bio's stock. These opinions can provide insight into Entera Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.